05/18/2023
“The venture arm is also a way for NYBC to apply its experience and capital to advance technologies for underserved areas of medicine…it is finalizing a deal to invest $2m in Aronora. A company developing drugs for blood diseases…generally raising venture capital in this field is difficult because of the perception that startups would need giant clinical studies to prove their drugs are effective in a range of patients who need anti clotting therapies…a startup can break into the market by targeting a narrower slice of the broad population… Aronora is developing its lead drug in patients on dialysis who can’t tolerate blood thinners…”
New York Blood Center and other healthcare nonprofits are using venture capital to help startups tackle diseases.